Bracco's ACIST Unit Gains FDA Clearance for Next-Gen Contrast System
Event summary
- ACIST Medical Systems, a Bracco subsidiary, received FDA clearance for its ACIST Pro™ Diagnostic System on May 18, 2026.
- The system reduces contrast use by 45ml per procedure and cuts procedure times by 5 minutes on average.
- ACIST Pro™ previously launched in Japan (2025) and select European markets (February 2026).
- Bracco CEO Fulvio Renoldi Bracco emphasizes improved diagnostic confidence and patient outcomes.
The big picture
Bracco's FDA clearance for ACIST Pro™ underscores the growing emphasis on precision and efficiency in interventional cardiology. The system's automated contrast delivery addresses key pain points in cath-lab procedures, aligning with broader industry trends toward reducing procedural risks and improving patient outcomes. With Bracco investing 9% of revenues in R&D, this launch reinforces its commitment to innovation in diagnostic imaging.
What we're watching
- Market Expansion
- The pace at which ACIST Pro™ gains adoption in the U.S. market compared to prior international launches.
- Clinical Impact
- Whether the system's documented efficiency gains translate into broader cath-lab workflow improvements.
- Competitive Positioning
- How Bracco leverages this technology to strengthen its leadership in contrast management solutions.
Related topics